Business Context and Reporting Period
This Form 8-K was filed by EyeGate Pharmaceuticals, Inc. (trading symbol: EYEG) on August 28, 2019. The report details a material corporate action approved by stockholders on June 20, 2019, and the Board of Directors, involving a 1-for-15 reverse stock split of the Company's common stock.
Key Financial Metrics
This filing is a current report regarding a corporate governance event and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Reverse Stock Split: A 1-for-15 reverse stock split was effected, combining 15 shares of common stock into 1 share.
- Effective Date: The split became effective at 12:01 a.m. Eastern Time on August 30, 2019.
- Trading Adjustments: Post-split shares began trading on The Nasdaq Capital Market on August 30, 2019, under a new CUSIP number (30233M 503) while retaining the "EYEG" symbol.
- Fractional Shares: No fractional shares were issued; holders received cash in lieu of fractions based on the closing price on August 29, 2019.
- Equity Instruments: Proportional adjustments were made to outstanding stock options, warrants, and shares reserved under the equity incentive plan.
Outlook, Risks, and Management Commentary
Purpose: The primary objective of the reverse stock split is to bring the Company into compliance with the minimum bid price requirements for maintaining its listing on The Nasdaq Capital Market.
Management Commentary: The filing notes that the split will decrease the number of outstanding shares but will not change the total number of authorized shares or the par value ($0.01 per share).
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the standard execution of the stock split and the associated cash payments for fractional shares.
Investor Verification Checklist
- Verify the new CUSIP number (30233M 503) for post-split trading.
- Confirm the adjusted number of shares held and any cash received for fractional shares.
- Review the adjusted exercise prices and share counts for any outstanding stock options or warrants.
- Monitor the stock price to ensure continued compliance with Nasdaq minimum bid price requirements.